Hint mode is switched on Switch off
For swift navigation between sections

Aurinia Pharmaceuticals
LEI 5299008YP2BW4570ML28

PDF download

Choose all Reset all
Download Cancel
Organization name
Aurinia Pharmaceuticals Inc
Country name
Canada
Country of registration
Canada
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

08/05/2026 Aurinia Pharmaceuticals: Completion Of Acquisition Or Disposition Of Assets, Financial Statements And Exhibits
07/05/2026 Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
30/03/2026 Aurinia Pharmaceuticals: Of This Report, Including Exhibit 99.1 Attached Hereto, Is Furnished Pursuant To Item 7.01 Of Form 8k And Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Sec Made By Aurinia Regardless Of Any General Incorporation Language In Such Filing, Except As Set Forth By Specific Reference In Such Filing, Financial Statements And Exhibits
06/03/2026 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Capital Efficiency Analysis
26/02/2026 Aurinia Pharmaceuticals: And Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (“the Exchange Act”), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. In Addition, The Information Included In This Current Report On Form 8k And The Exhibit Hereto, That Is Furnished Pursuant To This Item 2.02 Shall Not Be Incorporated By Reference In Any Of Aurinia's Filings Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Whether Made Before Or After The Date Hereof, Regardless Of Any General Incorporation Language In Such Filing, Except As Expressly Set Forth By Specific Reference In Such Filing, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
IV q eng
2019
IV q eng
2018
IV q eng
2017
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    5299008YP2BW4570ML28
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001600620
  • Business number (BN)
    804796027
  • EIN
    98-1231763
Registration is required to get access.